MediWound planning $100m Wall Street IPO

The chronic wounds and burns treatment company is planning to hold the offering at a company value of $450-500 million.

MediWound Ltd., which develops treatments for chronic wounds and burns is in talks with underwriters for a Wall Street IPO in the second quarter of 2014. The company plans to raise $100 million at a company value of $450-500 million.

Clal Biotechnology Industries Ltd. (TASE: CBI) owns 63% of MediWound. The company's NexoBrid gel for the removal of burn wound eschar has successfully completed clinical development and is approved and ready to launch in Europe.

Published by Globes [online], Israel business news - - on November 27, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018